Litman Gregory Wealth Management LLC Cuts Stock Position in Edwards Lifesciences Corporation $EW

Litman Gregory Wealth Management LLC lessened its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 10.4% in the 2nd quarter, HoldingsChannel reports. The fund owned 144,792 shares of the medical research company’s stock after selling 16,844 shares during the period. Litman Gregory Wealth Management LLC’s holdings in Edwards Lifesciences were worth $11,324,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of EW. Arlington Trust Co LLC boosted its position in shares of Edwards Lifesciences by 1.2% in the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock worth $804,000 after purchasing an additional 135 shares in the last quarter. Valeo Financial Advisors LLC raised its stake in Edwards Lifesciences by 2.8% in the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock valued at $372,000 after buying an additional 142 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after acquiring an additional 145 shares in the last quarter. Dakota Wealth Management boosted its holdings in Edwards Lifesciences by 2.5% in the second quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company’s stock worth $473,000 after acquiring an additional 146 shares in the last quarter. Finally, Leo Wealth LLC grew its stake in shares of Edwards Lifesciences by 1.2% during the first quarter. Leo Wealth LLC now owns 12,488 shares of the medical research company’s stock worth $905,000 after acquiring an additional 150 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 0.5%

Shares of EW stock opened at $77.03 on Monday. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00. The stock has a market cap of $45.22 billion, a P/E ratio of 11.08, a P/E/G ratio of 3.71 and a beta of 1.05. The stock has a 50 day moving average of $78.50 and a 200 day moving average of $76.01. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business’s revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on EW shares. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, July 25th. Argus upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Thursday, July 10th. Truist Financial raised their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a report on Friday, July 25th. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, July 25th. Finally, Royal Bank Of Canada upped their target price on Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $86.61.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.